Case Report

Migratory Polyarthritis Associated With Clopidogrel: A Case Report

Abstract

Clopidogrel, a selective thienopyridine, is used for secondary prevention of major adverse cardiovascular events. Some studies have reported inflammatory arthritis as a rare adverse effect of Clopidogrel. A 47-year-old male underwent percutaneous coronary intervention and was subsequently prescribed a 600 mg loading dose of Clopidogrel, followed by a daily dose of 75 mg. After six days of taking Clopidogrel, the patient presented to the emergency department with right knee pain. The knee joint exhibited swelling, warmth, and tenderness, although there was no redness or crusting. After two and six days of hospitalization, despite receiving antibiotics and Indomethacin, he developed arthritis of the metacarpophalangeal and metatarsophalangeal joints, respectively. According to the laboratory investigation, cultures, synovial fluid analysis, and imaging, infectious, rheumatologic, and crystallopathy diseases were ruled out for the patient. Clopidogrel was discontinued, and the patient was switched to ticagrelor 90 mg twice daily. All symptoms and signs of joint inflammation had improved within five days of stopping the Clopidogrel. After one week and one and six months of follow-up, there has been no recurrence of symptoms.

1. Makoui RH, Dizaji MS, Khederlou H. Comparison of serum levels of vitamin D in patients with and without acute coronary syndrome. Int J Cardiovas Pract 2018;3:25-9.
2. Hassanzadeh Makoui R, Moradlou M, Motamed N, Khederlou H. Comparison of the clinical manifestations of acute myocardial infarction in elderly and non-elderly patients admitted to the Coronary Care Unit of Ayatollah Mousavi Hospital of Zanjan. Alborz Univ Med J 2019;8:207-15.
3. Motedayen M, Khederlou H. ST-Segment Elevation Myocardial Infarction with Normal Coronary Arteries Angiography. Multidiscip Cardiovasc Ann 2020;11.
4. Agrawal S, Harburger J, Stallings G, Agrawal N, Garg J. Clopidogrel-induced recurrent polyarthritis. J Investig Med High Impact Case Rep 2013;1:2324709613500239.
5. Reny JL, Fontana P, Hochholzer W, Neumann FJ, ten Berg J, Janssen P, et al. Vascular risk levels affect the predictive value of platelet reactivity for the occurrence of major adverse cardiovascular events in patients on clopidogrel: Systematic review and collaborative meta-analysis of individual patient data. Circulation 2014;130:A19827.
6. Boulman N, Rozenbaum M, Slobodin G, Rosner I. Acute polyarthritis associated with clopidogrel treatment. Isr Med Assoc J 2005;7:670-1.
7. Ayesha B, Varghese J, Stafford H. Clopidogrel-associated migratory inflammatory polyarthritis. Am J Case Rep 2019;20:489-92.
8. Kawashiri S-y, Taguchi M, Kawakami A, Eguchi K. Clopidogrel-associated acute arthritis. Rheumatol Int 2012;32:449-50.
9. Garcia AE, Mada SR, Rico MC, Dela Cadena RA, Kunapuli SP. Clopidogrel, a P2Y12 receptor antagonist, potentiates the inflammatory response in a rat model of peptidoglycan polysaccharide-induced arthritis. PLoS One 2011;6:e26035.
10. Li Z, Sun L, Zhou Y, Ma H, Fang W, Wu C, et al. Analysis of the clinical characteristics of acute arthritis induced by clopidogrel. J Clin Pharm Ther 2021;46:1367-72.
Files
IssueVol 62 No 4 (2024) QRcode
SectionCase Report(s)
DOI https://doi.org/10.18502/acta.v62i4.17438
Keywords
Clopidogrel Arthritis Case report

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
How to Cite
1.
Khederlou H, Hassanzadeh-Makoui R, Azimi Pirsaraei V. Migratory Polyarthritis Associated With Clopidogrel: A Case Report. Acta Med Iran. 2024;62(4):233-235.